![]() |
市場調查報告書
商品編碼
2088960
血壓監測設備市場:2026-2032年全球市場預測(依產品類型、技術、連接方式、可攜性、應用、最終用戶和通路分類)Blood Pressure Monitoring Devices Market by Product Type, Technology, Connectivity, Portability, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,血壓監測設備市場規模將達到 84.9 億美元,複合年成長率為 8.71%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 47.3億美元 |
| 預計年份:2026年 | 51.4億美元 |
| 預測年份 2032 | 84.9億美元 |
| 複合年成長率 (%) | 8.71% |
血壓監測設備正逐漸成為高血壓預防、診斷、治療協調和長期管理的重要基礎設施。根據世界衛生組織(世衛組織)統計,全球約有12.8億30至79歲的成年人患有高血壓,但其中約46%的人對此毫不知情,只有約21%的人血壓得到有效控制。這種情況導致醫院、基層醫療中心、藥房、職場和居家醫療機構對經臨床檢驗的血壓監測儀的需求持續成長。
血壓監測設備市場正受到三大結構性因素的重塑:全球高血壓負擔、居家照護的普及以及對檢驗的數位化健康工作流程的需求。儘管出於環境和安全的考慮,水銀血壓計的使用量正在下降,但自動示波血壓計、24小時動態血壓監測和連網家用血壓監測儀的普及率卻在不斷提高。
人工智慧 (AI) 正在加速從單純的測量設備轉向決策支援生態系統的轉變。 AI 演算法可以協助醫療專業人員完成訊號品質評估、心律不整檢測、趨勢追蹤、用藥依從性提醒、風險分層以及突出顯示需要介入患者的儀表板等任務。這些功能在遠端患者監護中尤其重要,因為大量的家庭血壓數據可能會讓醫療團隊不堪負荷。
亞太地區血壓監測設備市場潛力大。這主要得益於中國和印度龐大的高血壓患者群體、日本作為全球老化程度最高的國家之一的地位,以及澳洲和韓國數位醫療的日益普及。都市化、心臟代謝風險的上升、基層醫療的擴展以及消費者對家用健康電子產品的熟悉程度,都推動了市場需求的成長。
在東協市場,由於都市區高血壓發病率上升、藥房篩檢加大以及行動醫療的普及,家用血壓監測正變得越來越普遍,儘管各國對保險報銷和檢驗的看法不盡相同。在海灣合作理事會國家,對慢性病管理和數位化醫療的投入不斷增加,整合式血壓監測設備在糖尿病、腎臟病和心血管風險管理計畫中發揮著至關重要的作用。
在美國,疾病管制與預防中心(CDC)的數據顯示,近一半的成年人患有高血壓,這使得檢驗的家用血壓監測儀和遠端患者監護的需求激增。在加拿大,國家監測系統發現約四分之一的成年人患有高血壓,促進了藥房、基層醫療機構和家庭血壓監測的發展。在墨西哥和巴西,由於心臟代謝風險較高,慢性病干預計畫正在擴展,而可負擔性和後續追蹤是影響計畫推廣的關鍵因素。
業界領導者應優先考慮經過臨床檢驗的上臂血壓監測儀、清晰的袖帶尺寸選擇以及符合 AAMI/ESH/ISO 81060-2 等認可檢驗協議。產品系列應明確區分診斷監測儀、家用監測儀、攜帶式血壓監測儀和促進健康的穿戴式裝置。
本執行摘要基於二手資訊來源了經檢驗的公共衛生和監管來源,包括世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、國家健康調查、臨床指南制定機構、醫療設備監管機構和高血壓協會。評估內容涵蓋疾病負擔、醫療服務模式、醫療設備檢驗標準、保險報銷趨勢和當地醫療基礎設施。
市場分析涵蓋多個方面,包括醫療設備類型、醫療服務環境、技術可行性、地理位置和終端用戶接受度。為避免未經證實的市場論點(例如不實的市場規模估算或預測假設),我們利用流行病學數據、政策指南、監管趨勢和可觀察到的醫療數位化趨勢對分析結果進行了檢驗。
血壓監測設備在全球從被動式心血管治療轉變為預防性慢性病管理的過程中發揮核心作用。最大的機會在於那些檢驗、可連網且易於使用的設備,這些設備能夠支援精準診斷、家庭監測、臨床追蹤和社區健康促進計畫。
The Blood Pressure Monitoring Devices Market is projected to grow by USD 8.49 billion at a CAGR of 8.71% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 4.73 billion |
| Estimated Year [2026] | USD 5.14 billion |
| Forecast Year [2032] | USD 8.49 billion |
| CAGR (%) | 8.71% |
Blood pressure monitoring devices are becoming essential infrastructure for prevention, diagnosis, treatment titration, and long-term management of hypertension. The World Health Organization reports that about 1.28 billion adults aged 30 to 79 live with hypertension globally, while roughly 46% are unaware of their condition and only about 21% have it controlled. This creates sustained demand for clinically validated blood pressure monitors across hospitals, primary care centers, pharmacies, workplaces, and home healthcare settings.
The industry is shifting from episodic office-based readings to continuous, connected, and patient-centered blood pressure management. Automated upper-arm monitors, ambulatory blood pressure monitoring systems, remote patient monitoring platforms, and validated home blood pressure monitors are increasingly favored because major clinical guidelines support out-of-office measurement to improve diagnostic accuracy and reduce white-coat and masked hypertension risk.
The blood pressure monitoring device landscape is being reshaped by three structural forces: the global hypertension burden, the movement of care into the home, and the need for validated digital health workflows. Mercury sphygmomanometers continue to decline because of environmental and safety concerns, while automated oscillometric devices, ambulatory blood pressure monitoring, and connected home monitors gain adoption.
Healthcare systems are prioritizing devices that integrate with electronic health records, telehealth programs, and remote patient monitoring reimbursement models. Buyers are also becoming more selective: clinically validated accuracy, appropriate cuff sizing, arrhythmia detection, ease of use, data privacy, and interoperability now influence procurement decisions as much as price.
Artificial intelligence is accelerating the transition from measurement-only devices to decision-support ecosystems. AI-enabled algorithms can support signal quality assessment, irregular heartbeat flagging, trend detection, adherence reminders, risk stratification, and clinician dashboards that highlight patients needing intervention. These capabilities are particularly valuable in remote patient monitoring, where large volumes of home blood pressure data can overwhelm care teams.
The cumulative impact of AI will depend on clinical validation, regulatory clearance, bias testing, and transparent performance across age groups, skin tones, pregnancy status, arrhythmias, and comorbidities. For cuffless and wearable blood pressure technologies, AI offers promise, but established standards still require rigorous validation before these tools can replace clinically validated cuff-based monitors for diagnosis or treatment decisions.
Asia-Pacific represents a high-volume opportunity for blood pressure monitoring devices because China and India carry very large hypertensive populations, Japan has one of the world's oldest populations, and Australia and South Korea have strong digital health adoption. Demand is supported by urbanization, rising cardiometabolic risk, expanding primary care, and consumer familiarity with home health electronics.
North America benefits from guideline-driven use of home and ambulatory blood pressure monitoring, strong telehealth infrastructure, and remote patient monitoring reimbursement pathways. Europe is shaped by strict medical device regulation, aging demographics, pharmacy-based screening, and broad use of validated devices in primary care. Latin America, led by Brazil and Mexico, shows growing demand for hypertension screening and home monitoring, although uneven access, affordability, and continuity of care remain barriers.
The Middle East, especially Gulf health systems, is investing in digital hospitals and chronic disease programs as diabetes, obesity, and hypertension converge. Africa has a substantial underdiagnosis challenge; scalable opportunities center on affordable validated monitors, community screening, solar or battery-resilient devices, and integration with primary healthcare programs.
ASEAN markets are moving toward broader home blood pressure monitoring as urban hypertension, pharmacy screening, and mobile health adoption increase, though reimbursement and validation awareness vary by country. The GCC is investing in chronic disease management and digitally connected care, making integrated blood pressure monitoring devices relevant for diabetes, kidney disease, and cardiovascular risk programs.
The European Union emphasizes compliance with the Medical Device Regulation, data protection under GDPR, and adoption of clinically validated devices across public and private care settings. BRICS economies combine large disease burden with price sensitivity, creating demand for scalable, durable, and localized manufacturing models. G7 markets remain centers for innovation, reimbursement design, and evidence generation for connected blood pressure monitoring. NATO countries add demand through military health, occupational screening, and resilient medical supply chain planning.
In the United States, CDC data show nearly half of adults have hypertension, creating strong demand for validated home monitors and remote patient monitoring. Canada's national surveillance identifies hypertension in roughly one in four adults, supporting pharmacy, primary care, and home-based monitoring. Mexico and Brazil face high cardiometabolic risk and expanding chronic disease programs, although affordability and follow-up capacity remain central adoption factors.
The United Kingdom, Germany, France, Italy, and Spain all face aging populations and high adult hypertension prevalence, making validated automatic blood pressure monitors important for primary care, pharmacies, and self-measurement. Russia's cardiovascular disease burden sustains the need for earlier detection and treatment monitoring.
China has more than 245 million adults with hypertension according to national studies, while India's NFHS-5 shows elevated blood pressure in about 24% of men and 21% of women aged 15 and older. Japan, Australia, and South Korea combine aging demographics with high digital readiness, supporting premium home monitors, ambulatory systems, and connected care models.
Industry leaders should prioritize clinically validated upper-arm devices, clear cuff-size options, and compliance with recognized validation protocols such as AAMI/ESH/ISO 81060-2. Product portfolios should distinguish between diagnostic-grade monitors, home-use devices, ambulatory blood pressure monitoring, and wellness-oriented wearables.
This executive summary is based on secondary research from verified public health and regulatory sources, including the World Health Organization, CDC, national health surveys, clinical guideline bodies, medical device regulators, and hypertension societies. The assessment considers disease burden, care-delivery models, device validation standards, reimbursement signals, and regional healthcare infrastructure.
Market interpretation was structured across device type, care setting, technology enablement, geography, and end-user adoption. Insights were triangulated using epidemiological data, policy guidance, regulatory direction, and observable healthcare digitization trends to avoid unsupported market claims, including unsupported sizing or forecasting assumptions.
Blood pressure monitoring devices are central to the global shift from reactive cardiovascular care to proactive chronic disease management. The strongest opportunities are in validated, connected, user-friendly devices that support accurate diagnosis, home monitoring, clinical follow-up, and population health programs.
As hypertension remains underdiagnosed and undertreated worldwide, manufacturers and healthcare partners that combine clinical accuracy, AI-enabled workflow support, affordability, and regulatory credibility will be best positioned to lead the next phase of blood pressure monitoring adoption.